Compare General Mills, Inc. (GIS) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Mills, Inc. vs Twist Bioscience Corp — how do they compare? General Mills, Inc. trades at $38.57 (market cap $19.46B), while Twist Bioscience Corp trades at $93.31 (market cap $5.76B). The key difference: General Mills, Inc. is far larger — about 3.4× Twist Bioscience Corp's market cap, and General Mills, Inc. pays a 6.69% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| GIS | TWST | |
|---|---|---|
Market Cap | $19.46B | $5.76B |
Sector | Consumer Staples | Health |
52-Week High | $51.27 | $102.88 |
52-Week Low | $32.17 | $24.16 |
Enterprise Value | $32.95B | $5.69B |
Dividend Yield | 6.69% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Mills (GIS) trades at $36.46, down 0.38% on the day, with a neutral technical signal and mixed earnings history. The stock shows a low P/E of 9.23 and pays a dividend, but faces net income margin pressure at -0.48% for 2026. Recent news highlights partnerships in regenerative agriculture and cost-saving initiatives targeting $3 billion by 2030 to combat soft consumer demand.
Outlook remains cautious with sales pressure expected in 2027, though valuation appears attractive. Key risks include competitive pressures and margin recovery challenges. Analyst consensus is mixed with a hold-heavy rating, suggesting patience for turnaround execution amid economic headwinds.
Twist Bioscience (TWST) trades at $92.61, up 2.5% on the day, with a bullish technical signal and strong analyst support. The company shows improving revenue growth ($377M in 2025, up 20% year-over-year) but continues to report significant losses (-$77.7M net income). Recent AI-driven drug discovery collaborations and product expansions provide growth catalysts, though persistent negative cash flow and insider selling present concerns.
Outlook remains cautiously optimistic with 79% analyst buy ratings and a $91.63 consensus target. Investment opportunity centers on AI-enabled synthetic biology growth, while risks include sustained profitability challenges, cash burn, and competitive pressures in genomics. The stock trades at premium valuations (P/S 13.74) despite negative margins.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About General Mills, Inc.
General Mills is a leading global packaged food company that produces snacks, cereal, convenient meals, yogurt, dough, baking mixes and ingredients, pet food, and superpremium ice cream. Its largest brands are Nature Valley, Cheerios, Old El Paso, Yoplait, Pillsbury, Betty Crocker, BLUE, and Haagen-Dazs. In fiscal 2022, 77% of its revenue was derived from the United States, although the company also operates in Canada, Europe, Australia, Asia, and Latin America. While most of General Mills' products are sold through retail stores to consumers, the company also sells products into the food-service channel and the commercial baking industry.
Read more on GIS →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
